patisiran (ALN-TTR02)

DRUG3 trials

Conditions

Amyloid NeuropathiesAmyloid Neuropathies, FamilialAmyloidosis, HereditaryAmyloidosis, Hereditary, Transthyretin-RelatedFamilial Amyloid PolyneuropathiesTTR-mediated AmyloidosisTransthyretin (TTR)-Mediated Amyloidosis

Phase 1

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

CompletedNCT02053454

Alnylam PharmaceuticalsTransthyretin (TTR)-Mediated Amyloidosis

Start: 2014-01-31End: 2014-06-30Updated: 2015-05-25

Phase 3

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

CompletedNCT01960348

Alnylam PharmaceuticalsAmyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Hereditary +3

Start: 2013-11-30End: 2017-08-31Updated: 2024-04-22

Unknown Phase

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

NCT02939820

Alnylam PharmaceuticalsAmyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Hereditary +3

Updated: 2024-05-20

2024-03-271 citations

Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Heart Journal2022-10-011 citations

Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial

Amyloid2022-09-1821 citations

Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Heart Journal2020-11-011 citations

S3155 Impact of Patisiran, an RNAi Therapeutic, on Diarrhea Symptoms in Patients With Hereditary Transthyretin-Mediated Amyloidosis

The American Journal of Gastroenterology2020-10-013 citations

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

Orphanet Journal of Rare Diseases2020-07-0851 citations

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Amyloid2020-03-0471 citations

P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2019-06-01

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis

JAMA Cardiology2019-03-1695 citations

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Circulation2019-01-17448 citations

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

New England Journal of Medicine2018-07-042779 citations

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

2017-09-11126 citations

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.

2015-09-04234 citations

patisiran (ALN-TTR02)

Sponsors

Conditions

Phase 1

Phase 3

Unknown Phase

Related Papers